• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Nurix Therapeutics (NRIX) Is Up 6.0% After Milestone From Sanofi And Phase 3 Start With Roche

    Simply Wall St·08/13/2026 00:38:23
    Listen to the news
    • Nurix Therapeutics recently reported earning a US$10 million milestone payment from Sanofi for advancing its oral STAT6 degrader into a Phase 1 trial, while also enrolling the first patient in a global Phase 3 study of its BTK degrader bexobrutideg in partnership with Roche for relapsed or refractory CLL/SLL.
    • Together, these updates highlight how Nurix’s DEL-AI protein degradation platform is now translating into late-stage clinical programs and tangible partnership revenues under its Sanofi and Roche collaborations.
    • Next, we will examine how the initiation of bexobrutideg’s Phase 3 trial with Roche shapes Nurix’s broader investment narrative.

    Uncover the next big thing with 19 elite penny stocks that balance risk and reward.

    What Is Nurix Therapeutics' Investment Narrative?

    For Nurix, the core investment story is about its DEL-AI platform converting into real clinical shots on goal and non-dilutive pharma funding. The Roche collaboration for bexobrutideg already reframed the stock around a potential BTK franchise, and the first Phase 3 enrollment now gives investors a clearer, registrational-stage catalyst to watch. The fresh US$10 million STAT6 milestone from Sanofi reinforces the partnered revenue stream, but is small next to Nurix’s rising R&D spend, so it likely does not change the near-term cash burn picture on its own. Instead, it slightly de-risks the platform narrative by adding another clinical-stage asset. The big swing factors still center on BTK degrader data, future Roche and Sanofi milestones, and whether losses widen faster than partnership cash arrives.

    However, the growing reliance on external milestones is something investors should be aware of. According our valuation report, there's an indication that Nurix Therapeutics' share price might be on the expensive side.

    Exploring Other Perspectives

    NRIX 1-Year Stock Price Chart
    NRIX 1-Year Stock Price Chart
    The Simply Wall St Community’s single fair value estimate sits at US$33.50, leaving plenty of room for disagreement as the Phase 3 BTK trial and ongoing cash burn remain the key swing factors investors need to weigh.

    Explore another fair value estimate on Nurix Therapeutics - why the stock might be worth as much as 26% more than the current price!

    The Verdict Is Yours

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Interested In Other Possibilities?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.